NCATS CTSA SIP RC2 Guide
Updated 6 official sources
Quick Answer: PAR-25-156 CTSA SIP RC2 eligibility turns on 7 checks: CTSA UM1 relationship, high-impact specialized capability, clinical and translational science gap, hub platform value, clinical-trial boundary, dissemination plan, and next-round timing.
Full answer and how we checked it
PAR-25-156 itself expired September 29, 2026; the successor, PAR-28-006, is a Grants.gov forecast with an estimated January 25, 2027 due date.
Who this is for: CTSA UM1 hubs, NCATS translational science teams, research platform leaders, clinical informatics groups, community-engagement teams, biostatistics and regulatory science groups, and sponsored-research offices deciding whether PAR-25-156 is the right route.
Data note: This guide uses the official NIH PAR-25-156 NOFO, Grants.gov listing 357634, NCATS CTSA context, and Grantsights award-data signals checked on May 19, 2026. Status, the successor forecast, and NIH RePORTER awards were rechecked on October 9, 2026.
In this guide
- 7 PAR-25-156 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This Proposal Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day CTSA SIP Readiness Plan
- What PAR-25-156 Required and Excluded
- What Reviewers Were Told to Weigh
- What Funded SIPs Look Like
- 6 Final Research Checks Before Submission
- 4 Decision Questions Before Writing
- 3 Last-Mile Checks For CTSA Hubs
- Sources
According to NIH PAR-25-156 (opens in a new tab), High Impact Specialized Innovation Programs support development and demonstration of unique hub capabilities, research platforms, or resources that address gap areas or roadblocks in clinical and translational science at CTSA Program Hubs. NIH lists the activity code as RC2 and marks clinical trials as optional.
This route is not a generic translational science project. The application has to fit the CTSA hub context and demonstrate a specialized capability or platform with value beyond routine local service.
Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NIH emergency competitive revision guide, NHLBI EIA guide, and the Grantsights grant database.
7 PAR-25-156 Eligibility Stop Checks
| Stop check | Strong CTSA SIP signal | Red flag |
|---|---|---|
| UM1 relationship | Applicant has eligible CTSA UM1 context | Hub eligibility is unclear |
| Specialized capability | Unique hub capability or platform is clear | Local service only |
| Translational science gap | Gap or roadblock is well-defined | Generic program improvement |
| Scale | Benefit can extend beyond one site | Local-only impact |
| Trial boundary | Clinical-trial optional status is explicit | Trial plan is vague |
| Dissemination | Adoption and sharing path are credible | Output stays internal |
| Timing | Hub is ready for the PAR-28-006 round | Hub approvals are late |
CTSA ideas weaken when they describe a useful hub service but not a translational science capability. This route needs the latter.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
5 Source Facts Applicants Should Know
According to NIH, SIPs support development and demonstration of unique hub capabilities, research platforms, or resources that address gap areas or roadblocks in clinical and translational science.
According to NIH, all applicant organizations and active award recipients for PAR-24-272 CTSA UM1 are eligible, and RC2 applications will only be awarded if there is an awarded UM1 application from the RC2 applicant organization. NIH marks clinical trials as optional.
According to USAspending.gov (opens in a new tab) data, the connected assistance listing (93.350) had about $588.2M in FY2024 obligations across 731 awards active that year.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-156 |
| Activity code | RC2 |
| Clinical trial status | Clinical Trials Optional |
| Status | Expired September 29, 2026; last due date was September 28, 2026 |
| Budget cap | $500,000 per year in direct costs, excluding consortium F&A |
| Project period | Up to 5 years |
| Successor | PAR-28-006, forecast with estimated due date January 25, 2027 |
| Live listing | Grants.gov listing 357634 |
What NIH Doesn't Tell You
Within 21 days, answer 4 practical questions. First, CTSA eligibility is a gate. If the UM1 relationship is not correct, the project idea does not matter.
Second, high impact should be specific. A hub building a shared clinical informatics platform to remove a translational science roadblock may fit. A hub requesting funds for routine program operations doesn't: the NOFO lists core services that supplement existing UM1 budgets as non-responsive.
Third, the application should show how the capability becomes usable by others. Dissemination, implementation, training, and resource sharing should not be late-stage decorations.
Fourth, the hub cap can block a good idea. A UM1 hub can submit no more than 2 RC2 applications as primary per due date and hold no more than 2 active RC2 awards as primary at once, and an RC2 in an extension period still counts toward that limit.
6 Evidence Assets That Make This Proposal Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the UM1 eligibility memo. State the CTSA UM1 status, applicant organization, hub roles, and award relationship.
Asset 2 is the translational science gap memo. Define the roadblock, affected stakeholders, current limitations, and why a specialized capability is needed.
Asset 3 is the capability map. Explain the platform, resource, method, service model, users, governance, and output.
Asset 4 is the dissemination and implementation plan. Show how the capability will be shared, adopted, evaluated, and sustained.
Asset 5 is the clinical-trial boundary memo. State whether trial work is included and how NIH clinical-trial instructions will be handled.
Asset 6 is the route memo. Compare PAR-25-156 with UM1 core work, administrative supplements, R01, R61/R33, U01, contracts, and institutional hub funds.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-156 RC2 | CTSA hub specialized capability fits | SIP route fits |
| UM1 core work | Work belongs in normal hub operations | Existing route may fit |
| Administrative supplement | Need is narrow and tied to UM1 | Smaller route may fit |
| R01 or U01 | Research project dominates | Research route may fit |
| Institutional funds | Local service dominates | Federal fit is weaker |
Warning: if the output is only a local service, don't start with PAR-25-156.
6 Bad-Fit Signals
First, CTSA UM1 eligibility is unclear. Second, the project is routine hub operations. Third, the translational science roadblock is vague.
Fourth, dissemination is weak. Fifth, clinical-trial status is not explained. Sixth, the budget is not tied to a specialized capability.
These signals are route risks.
21-Day CTSA SIP Readiness Plan
Days 1 through 3 should confirm UM1 status, hub role, clinical-trial boundary, and due date. Days 4 through 7 should write the UM1 eligibility and translational science gap memos.
Days 8 through 12 should build the capability map and dissemination plan. Days 13 through 16 should check budget, governance, evaluation, sharing, and partner roles. Days 17 through 21 should compare PAR-25-156 with UM1 core, supplement, R01, U01, and institutional routes.
What PAR-25-156 Required and Excluded
PAR-28-006 hasn't posted, so its terms aren't known. The expired NOFO is the best guide to what NCATS will likely ask for, and it was specific:
| Rule | PAR-25-156 text, summarized |
|---|---|
| Budget | No more than $500,000 per year in direct costs, excluding consortium F&A |
| Period | Up to 5 years |
| Required attachments | UM1 and RC2 Coordination and Integration Plan, Program Milestones table, Program Evaluation and Sustainability Plan |
| Travel | Budget for up to 3 people at a yearly in-person meeting |
| Award condition | RC2 funding depends on the primary UM1 hub being funded at the time of award |
| Clinical trials | Optional, but no trials beyond Phase IIB except Phase III trials for rare diseases |
The non-responsive list is where hubs get caught. NCATS said it wouldn't review applications proposing pilot or feasibility projects (those belong in the UM1 pilot module), traditional hypothesis-driven studies, dissemination of resources to other hubs, ancillary studies or logical extensions of ongoing work, core services that top up UM1 budgets, or work outside the NCATS strategic plan. Preliminary data wasn't required, but a strong rationale was.
What Reviewers Were Told to Weigh
Beyond standard NIH criteria, PAR-25-156 asked reviewers to judge whether the SIP:
- fills a real gap or removes a roadblock in clinical and translational science at the hub;
- would speed new science, resources, therapeutics, devices, software, or platforms across UM1 hubs if it works;
- produces a research resource or tool that's useful to the broader field, and how it'll be sustained after funding ends; and
- uses an approach well suited to the UM1 hub's needs.
Sustainability shows up twice, in the required evaluation plan and in review, so a platform with no plan for year 6 is a red flag.
What Funded SIPs Look Like
According to NIH RePORTER (opens in a new tab) records pulled October 9, 2026, NCATS made 3 new RC2 awards under PAR-25-156 and 2 under its predecessor, PAR-24-054:
| Award | Hub | Project | Award | Period |
|---|---|---|---|---|
| 1RC2TR006121-01 | University of Pennsylvania | Research Redesign to Reduce Chronic Conditions in Families | $3,312,892 | 2026-2030 |
| 1RC2TR005999-01 | Albert Einstein College of Medicine | ACTIVATE platform for comparative effectiveness and implementation in acute care | $3,176,515 | 2026-2030 |
| 1RC2TR004919-01A1 | University of California-Irvine | Machine learning-enabled metabolic imaging platform for drug efficacy testing | $3,024,289 | 2026-2030 |
| 1RC2TR004899-01A1 | University of Michigan | MOBILE mHealth platform for behavioral interventions (PAR-24-054) | $3,097,384 | 2025-2029 |
| 1RC2TR005123-01A1 | University of North Carolina at Chapel Hill | PROMOTER porcine translational model research (PAR-24-054) | $768,064 first year | 2025-2030 |
Grantsights checked these against the NOFO's budget rule. The 2026 awards were each obligated in one lump of about $3.0 million to $3.3 million covering roughly 4 years, while the UNC award is being paid yearly at about $770,000. Every recipient is an academic medical center with a CTSA hub, and 3 of the 5 won on resubmission (the "A1" suffix), so a first-round miss isn't the end of an idea. Most titles name a platform, which matches what reviewers were told to reward.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final checks. Check 1 is the NIH PAR-25-156 NOFO (opens in a new tab). Check 2 is CTSA UM1 eligibility. Check 3 is specialized capability fit. Check 4 is clinical-trial boundary. Check 5 is dissemination and implementation. Check 6 is whether PAR-28-006 has posted, and what changed from PAR-25-156.
You're ready when the team can state the UM1 relationship, translational science gap, specialized capability, users, clinical-trial status, and route reason in 6 direct sentences.
4 Decision Questions Before Writing
Within 21 days, ask 4 decision questions. Question 1: "Does the applicant have the required CTSA UM1 relationship?" Question 2: "What specialized capability or platform is being built?" Question 3: "What translational science roadblock is being addressed?" Question 4: "How will others adopt the output?"
If question 1 fails, stop and pick a different route.
3 Last-Mile Checks For CTSA Hubs
Within 21 days, run 3 last-mile checks. Check 1 is UM1 proof. Check 2 is specialized capability proof. Check 3 is dissemination proof.
If those checks are weak, talk to NCATS before building the narrative. A final note for applicants: write the SIP fit sentence before the overview. In 2 sentences, state the CTSA UM1 relationship, translational science gap, specialized capability, users, and reason PAR-25-156 is the best route.
Sources
Frequently Asked Questions
What does PAR-25-156 support?
It supports High Impact Specialized Innovation Programs that develop unique hub capabilities, research platforms, or resources for clinical and translational science.
Who is eligible?
NIH says applicant organizations and active award recipients for PAR-24-272 CTSA UM1 are eligible, and RC2 applications will only be awarded if there is an awarded UM1 from the RC2 applicant organization.
What activity code applies?
NIH lists RC2.
Is PAR-25-156 still open?
No. PAR-25-156 expired September 29, 2026 after its last due date of September 28, 2026. NCATS has forecast a successor, PAR-28-006, with an estimated due date of January 25, 2027; as of October 9, 2026 it hadn't posted.
Are clinical trials allowed?
Yes. NIH marks the NOFO as Clinical Trials Optional.
Who should skip this route?
Skip it when the organization does not have the required CTSA UM1 relationship or when the project is a local service rather than a high-impact specialized hub capability.
Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
NIH ALS Expanded Access U01 Eligibility
NIH ALS expanded access U01 guide for RFA-NS-26-001, trial-site eligibility, small-business IND sponsor rules, and route fit.
NIH AMP SCZ DPACC U24 eligibility Guide
NIH AMP SCZ DPACC U24 guide for single-source eligibility, June 9 2026 timing, $5M award signal, no-trial status, and NIMH route choices.